Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA546568 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR9204190.fastq.gz | Fastqsanger.gz | |||
| SRR9204200.fastq.gz | Fastqsanger.gz | |||
| SRR9204210_1.fastq.gz | Fastqsanger.gz | |||
| SRR9204210_2.fastq.gz | Fastqsanger.gz | |||
| SRR9204220_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 60 |
Similar Datasets
Project description:Despite progress in intensification of therapy, outcomes for patients with metastatic osteosarcoma (OS) have not improved in thirty years. We developed a system that enables preclinical screening of compounds against metastatic OS cells in the context of the native lung microenvironment. Using this strategy to screen a library of epigenetically-targeted compounds, we identified inhibitors of CDK12 to be most effective, reducing OS cell outgrowth in the lung by >90% at sub-micromolar doses. CDK12 inhibition led to defects in transcription elongation in a gene length- and expression-dependent manner. These effects were accompanied by defects in RNA processing and altered the expression of genes involved in transcription regulation and the DNA damage response. We further identify OS models that differ in their sensitivity to CDK12 inhibition in the lung and provide evidence that upregulated MYC levels may mediate these differences. Our studies provide a framework for rapid preclinical testing of compounds with anti-metastatic activity and highlight CDK12 as a potential therapeutic target in osteosarcoma.
2019-06-06 | GSE132233 | GEO
Project description:Despite progress in intensification of therapy, outcomes for patients with metastatic osteosarcoma (OS) have not improved in thirty years. We developed a system that enabled preclinical screening of compounds against metastatic OS cells in the context of the native lung microenvironment. Using this strategy to screen a library of epigenetically targeted compounds, we identified inhibitors of CDK12 to be most effective, reducing OS cell outgrowth in the lung by more than 90% at submicromolar doses. We found that knockout of CDK12 in an in vivo model of lung metastasis significantly decreased the ability of OS to colonize the lung. CDK12 inhibition led to defects in transcription elongation in a gene length- and expression-dependent manner. These effects were accompanied by defects in RNA processing and altered the expression of genes involved in transcription regulation and the DNA damage response. We further identified OS models that differ in their sensitivity to CDK12 inhibition in the lung and provided evidence that upregulated MYC levels may mediate these differences. Our studies provided a framework for rapid preclinical testing of compounds with antimetastatic activity and highlighted CDK12 as a potential therapeutic target in OS.
| S-EPMC6763270 | biostudies-literature
Project description:Cyclin-dependent kinase 12 (CDK12) overexpression is implicated in breast cancer, but whether it has a primary or only a cooperative tumorigenic role is unclear. Here, we show that transgenic CDK12 overexpression in the mouse mammary gland per se is sufficient to drive the emergence of multiple and multifocal tumors, while, in cooperation with known oncogenes or chemical carcinogens, it promotes earlier tumor onset and metastasis. Integrative transcriptomic, metabolomic and functional data revealed that enhanced glycolysis and hyperactivation of the serine-glycine-one- carbon network are metabolic hallmarks inherent to CDK12-induced tumorigenesis, which impose distinct metabolic dependencies in CDK12-transformed mammary epithelial cells. Consistently, in the retrospective analysis of adjuvant and neoadjuvant breast cancer patient cohorts and in prospective preclinical studies using primary-derived human breast tumor xenografts, CDK12-overexpressing breast cancers showed a more favorable disease course in response to methotrexate- based chemotherapy targeting CDK12-induced metabolic alterations, while appearing intrinsically refractory to other types of chemotherapy. Even more clinically relevant, in patients with hormone receptor-negative and lymph node-positive breast cancer who were randomized in an adjuvant phase III trial to 1-year low-dose metronomic methotrexate-based maintenance chemotherapy or no chemotherapy after standard adjuvant treatments, a high CDK12 status predicted a dramatic reduction in distant metastasis rate in the chemotherapy-treated vs. not-treated arm. Thus, by coupling tumor progression with metabolic reprogramming, CDK12 creates an actionable vulnerability for breast cancer therapy and might represent a suitable companion biomarker for targeted antimetabolite therapies in naturally occurring human breast cancers.
2022-02-22 | GSE189274 | GEO
Project description:We describe the epigenetic profiling of the H3K9me2 and HP1a in Drosophila third instar larvae before and after CDK12 depletion by RNA interference (RNAi). Here we show that CDK12 regulates heterochromatin dynamics in Drosophila chromosomes. Depletion of CDK12 induces the increased HP1a and H3K9me2 binding profile on the coding region of euchromatic genes, with the X chromosome being the most affected. These results are consistent with the polytene chromosome immunostaining pattern of HP1a and H3K9me2 after CDK12 knockdown in our initial cytological observations, which show that CDK12 depletion induce heterochromatin spreading on euchromatic arms, especially on the X chromosome. This study describes a novel role of the CDK12 complex in controlling the epigenetic transition between euchromatin and heterochromatin. Examination of the genome-wide H3K9me2 and HP1a binding profile in wildtype larvae (WT) and CDK12-depleted larvae (CDK12-KD). Examination of the genome-wide CDK12 binding profile in wildtype larvae (WT). Twelve independent immunoprecipitations were conducted for each antibody. Two biological replicates were performed.
2015-11-02 | E-GEOD-63011 | biostudies-arrayexpress
Project description:In a forward genetic screen, we have previously identified a null mutant of Cdk12 that results in alterations in actin dynamics, the axon initial segment and electrophysiology in Drosophila melanogaster. To decipher how Cdk12 may be having these effects, we extracted RNA from pooled Drosophila heads and compared Cdk12-null mutants to controls at the transcriptome level.
2023-01-01 | E-MTAB-12090 | biostudies-arrayexpress
Project description:Osteosarcoma (OS) is the most common primary bone tumour in children and young adults, and the second highest cause of cancer-related death in this age group. In spite of aggressive chemotherapy, disease-free survival has not improved significantly in the past 20 years, and 50% of patients subsequently develop fatal pulmonary metastasis. We have performed gene expression profiling of primary osteosarcoma biopsies (i) to identify prognostic markers, and (ii) to identify novel therapeutic targets. Keywords: Comaprison between disease status (metastatic vs non-metastatic) and normal
2010-08-30 | GSE9508 | GEO
Project description:We report MAPK7-MMP9 signalling axis in metastatic osteosarcoma
2020-07-27 | GSE140131 | GEO
Project description:Determining interaction partners with CDK12 using IP-MS. Capturing global proteome expression changes as a result of CDK12 knockdown.
2017-03-21 | PXD004184 | Pride
Project description:To investigate the effect of CDK12/13 inhibition and MYC over-expression on gene expression of high-risk Group 3 medulloblastoma cells, we established D341 cells treated or not with 100 nM THZ531 for 6 hours and silenced (siMYC) or not (siCtrl) for MYC expression for 48 hrs, respectively.
2023-09-13 | GSE225375 | GEO